New Business Opportunities in Bio/Pharma,
Medical Devices & Diagnostics

May 2017

Welcome to the May 2017 issue of PharmSource PERISCOPE

This monthly e-newsletter provides valuable insight to sales and marketing professionals who sell goods and services to bio/pharma, medical device or diagnostic companies. It helps you recognize new business opportunities and overcome sales obstacles.

Enjoy the May issue!

The PharmSource Team


PMA Approvals for Medical Devices and Diagnostics

by Judy Nanthavong, Senior Research Analyst

The Devices and Diagnostics edition of the PharmSource Lead Sheet focuses on high risk devices that require Premarket Approval (PMA) from the US FDA. If we take a look at data extracted from the FDA’s database and the PharmSource Lead Sheet database, we can observe PMA approval trends over time.

As shown in Figure 1, the number of original PMA approvals increased from 2013 to 2015. The sharp increase in PMA approvals in 2015 could have been related to… read on

PharmSource Lead Sheet
Summary of Global Clinical Pipeline Activity

Lead Type April 2017 YTD 2017
Early Development 130 434
Late Development 115 424
Biologic 118 409
Small Molecule 263 963
Parenteral 131 449
Oral 97 364
New Financings 81 329
Total Drug Leads 417 1469
Total Device &
Diagnostic Leads
150 578

*Total leads include acquisitions/alliances, company acquisition/alliances and events.


Pipeline Tip

Stealth BioTherapeutics initiates the CHALLENGE-HD Phase I/II study with SBT-20 for the treatment of patients with early-stage Huntington disease:

  • Therapeutic Area: Neurology/CNS
  • Dosage Form: Parenteral
  • API: Peptide – Chemical

Get deeper information about the likely upcoming needs of Stealth BioTherapeutics, its pipeline, contacts and more in the PharmSource Lead Sheet. If you’re not yet a subscriber, click here to learn more.

Follow the Money to

Bio/Pharmaceutical Opportunities

Spotlight on ContraVir Pharmaceuticals, Inc.

ContraVir Pharmaceuticals is a U.S. public bio/pharmaceutical company that develops and commercializes targeted antiviral therapies for the treatment of Hepatitis B, shingles and shingles pain. They plan to raise $12 million in a secondary public offering.

What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to fund R&D activities and ongoing clinical trials of its pipeline, which may include… read on

Follow the Money to

Medical Device & Diagnostic Opportunities

Spotlight on Aspect Imaging, Inc.

Aspect Imaging is a private company based in Israel that develops and manufactures preclincial MRI systems. They raised $30 million in the completion of a venture capital investment.

What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to support the development of its Embrace Neonatal MRI system and its stroke-dedicated MRI system… read on

M&A in the CMC Services Industry: Implications and Outlook

PharmSource’s just-released trend report, M&A in the CMC Services Industry: Implications and Outlook, analyzes how M&A in the bio/pharma contract services industry is likely to play out over the next two years. Key questions it addresses include:

1. Which capabilities are likely to be most in demand by acquirers?

2. Which companies are likely to be the most active acquirers?

3. What developments would most likely slow M&A activity?


The Contract Services Market: Status and Strategies

PharmSource president, Jim Miller, will share his perspective on the contract services landscape and suggest strategies for outsourcing companies looking to grow in this sector at CPhI North America.

For more information click here.

PharmSource Lead Sheet

The PharmSource Lead Sheet is the industry’s definitive source for identifying targeted new business opportunities in bio/pharmaceutical companies around the world. Our dedicated research team knows how and where to find fresh, targeted leads, and we have the contact information you need to start the sales process.

Don’t be the last to learn about the latest business development opportunities. If you’re not already using the Lead Sheet, contact us today to schedule a complimentary test-drive.

See for yourself how this resource can be a vital tool for building your brand and growing your market share.

To request a test-drive today, contact Nathaniel Celentano at / 1-703-383-4903, ext. 112 (ET USA).